^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Adcitmer (McSAF 03)

    i
    Other names: McSAF 03
    Company:
    McSAF, University of Tours
    Drug class:
    Microtubule inhibitor, CD56-targeted antibody-drug conjugate
    Related drugs:
    9ms
    Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers. (PubMed, J Immunother Cancer)
    Finally, the therapeutic performance of Adcitmer and its aglycosylated form was assessed in an MCC xenograft mouse model.Investigating the Adcitmer interaction with immune cells demonstrated that it is mostly mediated by Fc recognition. Accordingly, Adcitmer aglycosylation led to reduced immune cell toxicity and strikingly also to improved therapeutic performance even in an MCC xenograft model using immunodeficient mice.Our study suggests that aglycosylated Adcitmer should be considered as a therapeutic option in patients with advanced MCC or other CD56-positive tumors.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • ANXA5 (Annexin A5)
    |
    Adcitmer (McSAF 03)